NASDAQ:KURA - Kura Oncology Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $15.76 -0.36 (-2.23 %) (As of 01/18/2019 08:00 AM ET)Previous Close$16.12Today's Range$15.71 - $16.2252-Week Range$10.20 - $24.02Volume170,200 shsAverage Volume269,728 shsMarket Capitalization$613.16 millionP/E RatioN/ADividend YieldN/ABeta3.16 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in San Diego, California. Receive KURA News and Ratings via Email Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KURA Previous Symbol CUSIPN/A Webwww.kuraoncology.com Phone858-500-8800Debt Debt-to-Equity Ratio0.02 Current Ratio14.76 Quick Ratio14.76Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.64 per share Price / Book5.97Profitability EPS (Most Recent Fiscal Year)($1.52) Net Income$-35,430,000.00 Net MarginsN/A Return on Equity-44.83% Return on Assets-39.47%Miscellaneous Employees32 Outstanding Shares38,040,000Market Cap$613.16 million OptionableOptionable Kura Oncology (NASDAQ:KURA) Frequently Asked Questions What is Kura Oncology's stock symbol? Kura Oncology trades on the NASDAQ under the ticker symbol "KURA." How were Kura Oncology's earnings last quarter? Kura Oncology Inc (NASDAQ:KURA) released its earnings results on Monday, November, 5th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.01. View Kura Oncology's Earnings History. When is Kura Oncology's next earnings date? Kura Oncology is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Kura Oncology. What price target have analysts set for KURA? 5 analysts have issued twelve-month price targets for Kura Oncology's shares. Their predictions range from $25.00 to $32.00. On average, they expect Kura Oncology's stock price to reach $29.00 in the next year. This suggests a possible upside of 84.0% from the stock's current price. View Analyst Price Targets for Kura Oncology. What is the consensus analysts' recommendation for Kura Oncology? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kura Oncology. What are Wall Street analysts saying about Kura Oncology stock? Here are some recent quotes from research analysts about Kura Oncology stock: 1. According to Zacks Investment Research, "Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. " (1/8/2019) 2. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating and $31 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (12/3/2018) Has Kura Oncology been receiving favorable news coverage? Media stories about KURA stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kura Oncology earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. Who are some of Kura Oncology's key competitors? Some companies that are related to Kura Oncology include Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Endo International (ENDP), Reata Pharmaceuticals (RETA), Arena Pharmaceuticals (ARNA), Heron Therapeutics (HRTX), Opko Health (OPK), Ironwood Pharmaceuticals (IRWD), Mirati Therapeutics (MRTX), Supernus Pharmaceuticals (SUPN), Endocyte (ECYT), Innoviva (INVA), Xencor (XNCR) and AnaptysBio (ANAB). Who are Kura Oncology's key executives? Kura Oncology's management team includes the folowing people: Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 49)Dr. Antonio Gualberto, Head of Devel. & Chief Medical Officer (Age 53)Dr. Marc Grasso, CFO & Chief Bus. OfficerMr. John Farnam, Chief Operating OfficerMr. Pete De Spain, VP of Investor Relations & Corp. Communications How do I buy shares of Kura Oncology? Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Kura Oncology's stock price today? One share of KURA stock can currently be purchased for approximately $15.76. How big of a company is Kura Oncology? Kura Oncology has a market capitalization of $613.16 million. The company earns $-35,430,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. Kura Oncology employs 32 workers across the globe. What is Kura Oncology's official website? The official website for Kura Oncology is http://www.kuraoncology.com. How can I contact Kura Oncology? Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected] MarketBeat Community Rating for Kura Oncology (NASDAQ KURA)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 238 (Vote Outperform)Underperform Votes: 199 (Vote Underperform)Total Votes: 437MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe KURA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/18/2019 by MarketBeat.com StaffFeatured Article: What is a Tariff?